Theriva Biologics, Inc. TOVX

TOVX Company Overview

Theriva Biologics, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer and related diseases through oncolytic virus platforms and immuno-oncology approaches. The company operates primarily within the biotechnology and biopharmaceutical industries, with a concentration on therapies designed to selectively target tumor cells while stimulating anti-tumor immune responses. Theriva’s principal development programs have included the investigational oncolytic adenovirus candidate VCN-01, as well as earlier-stage therapeutic and vaccine-related research initiatives. The company’s revenue profile has historically been limited because it remains in the clinical development stage and has not commercialized a product approved for broad market sale.

Theriva Biologics evolved from earlier biotechnology operations conducted under the name Synthetic Biologics, Inc. before rebranding to reflect a strategic emphasis on oncology and viral immunotherapy. The company’s positioning has centered on the development of tumor-selective viral therapies designed to improve delivery into solid tumors and potentially enhance the effectiveness of existing cancer treatments. Its strategic differentiation has been tied to intellectual property surrounding adenoviral platforms engineered for tumor penetration and immune activation in difficult-to-treat cancers such as pancreatic cancer and retinoblastoma.